Loading company…
ZytoMax develops clinical diagnostic products, including tests for prostate cancer.
Founded in 2021 and based in Berlin, ZytoMax develops diagnostic products for cancer detection, including immunohistochemical tests that distinguish benign from malignant prostate disease. It serves healthcare providers and laboratories in Europe. Archimed acquired the company alongside its management in January 2021; financial terms were not disclosed.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in